Acumen Pharmaceuticals, Inc.

ABOS

Held by 1 specialist biotech fund

Share on X

Fund Holdings

RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management29.5%Mar 17, 2026

SC 13D/ARA Capital Management24.8%Mar 31, 2025

SC 13D/A

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 14,932,063Value: $31.5M

**Signal Note: RA Capital initiates $31.5M position in Acumen (ABOS)** RA Capital's entry into Acumen likely reflects conviction in södintobitus (senoprotein mimetic) for early Alzheimer's disease, where the company is advancing Phase 2b data expected in 2H 2024. The $31.5M stake (~5% of market cap) signals a crossover investor's confidence in a mechanistically differentiated approach targeting soluble tau oligomers, a validated pathology target with less crowded competitive landscape than anti-amyloid monoclonal antibodies.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SLDB1 fund SION1 fund SPRY1 fund TSHA1 fund PCSC1 fund RNA1 fund QGEN1 fund VOR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: